# US 11,077,045 B2 · Blood microperfusion to skin by Shilajit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,045 B2
- Document ID: US11077045B2
- Status: Granted
- Kind: B2
- Application number: 16/018,876
- Filed: 2018-06-26
- Published: 2019-12-26
- Granted: 2021-08-03
- Earliest claimed: 2018-06-26
- Assignees: Natreon, Inc.
- Applicants: Natreon, Inc.
- Inventors: Chandan K. Sen; Sanyasi R. Kalidindi
- Web page: https://patentgrep.com/patent/US11077045B2

## CPC

- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 35/02: from inanimate materials (carbon A61K33/44)
- A61K 8/368: with carboxyl groups directly bound to carbon atoms of aromatic rings
- A61K 8/411: {Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/66: Enzymes
- A61K 8/72: containing organic macromolecular compounds
- A61K 8/92: Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K 8/965: {of inanimate origin}
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/92: Oral administration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Methods of using Shilajit or its individual components, or a combination of two or more of these components, to improve skin microperfusion, to upregulate ECM related genes in the skin, to increase endothelial cell migration and growth of blood vessels, and thus to improve skin health are presented herein.

## Claims

### Claim 1

A method of improving skin microperfusion comprising the step of administering daily for at least 14 weeks to a mammal in need of such treatment a therapeutically effective amount of Shilajit or its individual components, or a combination of two or more of these components, to improve skin microperfusion of the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administration of Shilajit or its individual components, or a combination of two or more of these components induces upregulation of at least one gene involved in the movement of endothelial cells, an endothelial cell migration cluster, and/or growth of blood vessels through the TGFβ1 and VEGFA pathway.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 4 (depends on 2)

The method of claim 2, wherein the at least one upregulated endothelial cell migration cluster gene is selected from the group consisting of Integrin alpha-5 (ITGA5), Junctional adhesion molecule 3 (JAM3), Galectin-1 (LGALS1), Lysyl oxidase (LOX), Matrix metallopeptidase-2 (MMP2), Platelet-derived growth factor receptor beta (PDGFRB), Protein kinase, CGMP-dependent, Type 1 (PRKG1), Reversion inducing cysteine rich protein with kazal motifs (RECK), Serpin peptidase inhibitors family F (SERPINF), Secreted protein acidic and cysteine rich (SPARC), Thrombospondin 2 (THBS2), TIMP metallopeptidase inhibitor 1 (TIMP1), TIMP metallopeptidase inhibitor 2 (TIMP2), and Tenascin N (TNN).

### Claim 5 (depends on 1)

The method of claim 1, wherein the individual components of Shilajit comprise 3-hydroxy-dibenzo-α-pyrone, 3,8-dihydroxy-dibenzo-α-pyrone, dibenzo-α-pyrone chromoproteins, humic acid, fulvic acid, and minerals.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammal is a human, and wherein the dose of Shilajit is from about 20 mg to about 2,000 mg per day in humans.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mammal is a human, and wherein the dose of Shilajit is from about 100 mg to about 500 mg per day in humans.

### Claim 8 (depends on 2)

The method of claim 2, wherein the mammal is a human, and wherein the dose of Shilajit is from about 250 mg to about 2,000 mg/day.

### Claim 9 (depends on 1)

The method of claim 1, consisting essentially of said administering step.